Wide Ranks

APVO

Aptevo Therapeutics Inc.

0.3453

Top Statistics
Market Cap 6 M Forward PE -0.3352 Revenue Growth 0.00 %
Current Ratio 1.70 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.1430 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 7 M Total Cash Per Share 0.4190 Total Debt 4 M
Total Debt To Equity 109.28 Current Ratio 1.70 Book Value Per Share 0.2590
All Measures
Short Ratio 5.00 % Message Board Id finmb_331280020 Fax 206 838 0503
Shares Short Prior Month 154732 Return On Equity -2.51 City Seattle
Uuid 470316e1-b879-3a10-830d-ae029cd54a71 Previous Close 0.3360 First Trade Date Epoch Utc 1 B
Book Value 0.2590 Beta 5.07 Total Debt 4 M
Volume 1 M Price To Book 1.33 Last Split Date 1 B
Fifty Two Week Low 0.1380 Total Cash Per Share 0.4190 Shares Short Previous Month Date 1 B
Target Median Price 8.00 Max Age 86400 Sand P52 Week Change 0.3133
Target Mean Price 8.00 Net Income To Common -24014000 Short Percent Of Float 0.0397
Implied Shares Outstanding 18 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 2 M Average Volume10days 2 M Total Cash 7 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0003 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.3360
Target Low Price 8.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.2264
Open 0.3380 Free Cashflow -14678500 State WA
Dividend Yield 0.00 % Return On Assets -0.7275 Time Zone Short Name EST
Trailing Eps -11.24 Day Low 0.3064 Address1 2401 4th Avenue
Shares Outstanding 18 M Price Hint 4 Target High Price 8.00
Website https://www.aptevotherapeutics.com 52 Week Change -0.9581 Average Volume 6 M
Forward Eps -5.83 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 131.80 % Last Split Factor 1:44 Regular Market Day High 0.3520
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 109.28
Fifty Two Week High 10.80 Day High 0.3520 Shares Short 734635
Regular Market Open 0.3380 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0397 Operating Cashflow -23279000
Currency USD Time Zone Full Name America/New_York Market Cap 6 M
Is_nasdaq_100 False Zip 98121 Quote Type EQUITY
Industry Biotechnology Long Name Aptevo Therapeutics Inc. Regular Market Day Low 0.3064
Held Percent Institutions 0.1136 Current Price 0.3453 Address2 Suite 1050
Enterprise To Ebitda -0.1430 Financial Currency USD Current Ratio 1.70
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 17 M Two Hundred Day Average 1.39 Enterprise Value 3 M
Forward PE -0.3352 Regular Market Volume 1 M Ebitda -24207000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.

It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.

It is also developing ALG.

APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer.

The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.

APV-527.

Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.